SciFi detector and associated method for real-time determination of profile and output factor for small fields in stereotactic radiotherapy.

PURPOSE: For determining small-field profile and output factor during stereotactic radiotherapy quality assurance (QA) procedures, we propose a novel system based on the scintillating fiber (SciFi) detector with output image acquisition and processing to allow real-time monitoring of profile and output factor. MATERIALS AND METHODS: The employed detector is a SciFi detector made of tissue-equivalent scintillating plastic fibers arranged in 6-layer fiber ribbons with a fiber pitch of 275 µm in each layer. The scintillating signal at the detector output is acquired by a sCMOS (scientific complementary metal-oxide-semiconductor) camera and represents the projected field profile along the fibers axis. An iterative reconstruction method of the field from its projected profile based on a priori knowledge of some features of the radiation field defined by the stereotactic cones is suggested. The detector with implemented data processing has been tested in clinical conditions, for determining beam profiles and output factors, using cone collimators of different sizes from 4 to 15 mm diameter. The detector under test was placed at 1.4 cm depth and 98.6 cm source to surface distance (SSD) in a water-equivalent phantom and irradiated by a 6 MV photon beam. RESULTS: The reconstructed field profiles obtained from the detector are coherent with data from EBT3 radiochromic films, with differences within ±0.32 mm for both the FWHM and the penumbra region. For real-time determination of the field output factor, the measured data are also in good agreement with data independently determined by the French Institute for Radiological Protection and Nuclear Safety (IRSN) based on radiochromic films and thermoluminescent 1 × 1 mm2 micro-cubes dosimeters (TLD). The differences are within ±1.6% for all the tested cone sizes. CONCLUSIONS: We propose and have tested a SciFi plastic scintillating detector with an optimized signal processing method to characterize small fields defined by cone collimators. It allows the determination of key field parameters such as full width at half maximum (FWHM) and field output factors. The results are consistent with those independently measured using TLD and radiochromic films. As the SciFi detector does not require a correction factor, it is in line with the International Atomic Energy Agency (IAEA) and the American Association of Physicists in Medicine (AAPM) TRS-483 recommendations, and can be suitable for online QA of small radiation fields used in photon beam radiotherapy, and is compatible with MRI-LINAC.

Design and testing of a phantom and instrumented gynecological applicator based on GaN dosimeter for use in high dose rate brachytherapy quality assurance.

PURPOSE: High dose rate brachytherapy (HDR-BT) is widely used to treat gynecologic, anal, prostate, head, neck, and breast cancers. These treatments are typically administered in large dose per fraction (>5 Gy) and with high-gradient-dose-distributions, with serious consequences in case of a treatment delivery error (e.g., on dwell position and dwell time). Thus, quality assurance (QA) or quality control (QC) should be systematically and independently implemented. This paper describes the design and testing of a phantom and an instrumented gynecological applicator for pretreatment QA and in vivo QC, respectively. METHODS: The authors have designed a HDR-BT phantom equipped with four GaN-based dosimeters. The authors have also instrumented a commercial multichannel HDR-BT gynecological applicator by rigid incorporation of four GaN-based dosimeters in four channels. Specific methods based on the four GaN dosimeter responses are proposed for accurate determination of dwell time and dwell position inside phantom or applicator. The phantom and the applicator have been tested for HDR-BT QA in routine over two different periods: 29 and 15 days, respectively. Measurements in dwell position and time are compared to the treatment plan. A modified position-time gamma index is used to monitor the quality of treatment delivery. RESULTS: The HDR-BT phantom and the instrumented applicator have been used to determine more than 900 dwell positions over the different testing periods. The errors between the planned and measured dwell positions are 0.11 ± 0.70 mm (1σ) and 0.01 ± 0.42 mm (1σ), with the phantom and the applicator, respectively. The dwell time errors for these positions do not exhibit significant bias, with a standard deviation of less than 100 ms for both systems. The modified position-time gamma index sets a threshold, determining whether the treatment run passes or fails. The error detectability of their systems has been evaluated through tests on intentionally introduced error protocols. With a detection threshold of 0.7 mm, the error detection rate on dwell position is 22% at 0.5 mm, 96% at 1 mm, and 100% at and beyond 1.5 mm. On dwell time with a dwell time threshold of 0.1 s, it is 90% at 0.2 s and 100% at and beyond 0.3 s. CONCLUSIONS: The proposed HDR-BT phantom and instrumented applicator have been tested and their main characteristics have been evaluated. These systems perform unsupervised measurements and analysis without prior treatment plan information. They allow independent verification of dwell position and time with accuracy of measurements comparable with other similar systems reported in the literature.

Potential interest of developing an integrated boost dose escalation for stereotactic irradiation of primary prostate cancer.

INTRODUCTION: The stereotactic irradiation is a new approach for low-risk prostate cancer. The aim of the present study was to evaluate a schema of stereotactic irradiation of the prostate with an integrated-boost into the tumor. MATERIAL AND METHODS: The prostate and the tumor were delineated by a radiologist on CT/MRI fusion. A 9-coplanar fields IMRT plan was optimized with three different dose levels: 1) 5 × 6.5 Gy to the PTV1 (plan 1), 2) 5 × 8 Gy to the PTV1 (plan 2) and 3) 5 × 6.5 Gy on the PTV1 with 5 × 8 Gy on the PTV2 (plan 3). The maximum dose (MaxD), mean dose (MD) and doses received by 2% (D2), 5% (D5), 10% (D10) and 25% (D25) of the rectum and bladder walls were used to compare the 3 IMRT plans. RESULTS: A dose escalation to entire prostate from 6.5 Gy to 8 Gy increased the rectum MD, MaxD, D2, D5, D10 and D25 by 3.75 Gy, 8.42 Gy, 7.88 Gy, 7.36 Gy, 6.67 Gy and 5.54 Gy. Similar results were observed for the bladder with 1.72 Gy, 8.28 Gy, 7.01 Gy, 5.69 Gy, 4.36 Gy and 2.42 Gy for the same dosimetric parameters. An integrated SBRT boost only to PTV2 reduced by about 50% the dose difference for rectum and bladder compared to a homogenous prostate dose escalation. Thereby, the MD, D2, D5, D10 and D25 for rectum were increased by 1.51 Gy, 4.24 Gy, 3.08 Gy, 2.84 Gy and 2.37 Gy in plan 3 compared to plan 1. CONCLUSIONS: The present planning study of an integrated SBRT boost limits the doses received by the rectum and bladder if compared to a whole prostate dose escalation for SBRT approach.

Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images.

PURPOSE: Gold markers are frequently used for a better daily repositioning of the prostate before irradiation. The purpose of this work was to analyze if the combination of an androgen deprivation with the external irradiation could modify the position of the gold markers in the prostate. PATIENTS AND METHODS: Ten patients have been treated for a prostate cancer, using three implanted gold markers. The variations of the intermarker distances in the prostate were measured and collected on daily OBI(®) kilovoltage images acquired at 0° and 90°. Five patients had a 6-month androgen deprivation started before the external irradiation (H group) and five did not (NH group). RESULTS: A total number of 1062 distances were calculated. No distance variation greater than 3.7mm was seen between two markers, in any of the two groups. The median standard deviations of the daily intermarker distance differences were 0.7mm (range 0.3-1.2mm) for the H group and 0.6mm (range 0.2-1.2mm) for the NH group. The intermarker distances variations were noted as greater than -2mm, between -2mm and 2mm and greater than 2mm in 16.4, 83.4 and 0.2% for the H group and 1.3, 98.5 and 0.2% for the NH group, respectively. CONCLUSION: The distance variations remained less than 4mm in both groups and for all the measurements. In the NH group, the variation of the distance between two markers remained below 2mm in 98.5%. In the H group, the presence of a reduction of distance above 2mm in 16.4% of measurements could indicate the shrinkage of the prostate volume.

Fiber background rejection and crystal over-response compensation for GaN based in vivo dosimetry.

For dosimetric measurements using an implantable optical fiber probe with GaN (Gallium Nitride) scintillator as radioluminescence (RL) transducer, a bi-channel method is proposed to reject the background contribution of the irradiated fiber segment. It is based on spectral differences between the narrow-band light emission from GaN and the large-band background from the irradiated optical fiber. Experimental validation of this method using 6 MV photon beam has shown that the remaining background contribution after subtraction is below 1.2% for square field sizes ranging from 3 cm to 20 cm. Furthermore, a compensation method for the over-response of GaN is also proposed, since GaN is not tissue equivalent. The over-response factor of GaN exhibits a linear increase with square field aperture and depends on depth from phantom surface. This behaviour is modelled to allow compensation in specific conditions. The proposed method has been evaluated and has shown a maximum deviation of 3% for a 6 MV photon beam and 1% for an 18 MV photon beam at a depth beyond the build-up region.